Langenfeld, Germany

Andreas Kollmeyer-Seeger


Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 86(Granted Patents)


Company Filing History:


Years Active: 2002-2003

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Andreas Kollmeyer-Seeger

Introduction

Andreas Kollmeyer-Seeger is a notable inventor based in Langenfeld, Germany. He has made significant contributions to the field of transdermal therapeutic systems, holding a total of 2 patents. His work focuses on innovative methods for drug delivery that enhance patient care and treatment efficacy.

Latest Patents

Kollmeyer-Seeger’s latest patents include a transdermal therapeutic system (TTS) containing oxybutynin. This system allows for the transcutaneous administration of oxybutynin over several days, utilizing a method for production that does not require solvents. The TTS features a matrix mass with oxybutynin in a self-adhesive layer, incorporating ammonium-group-containing (meth)acrylic polymers, at least one citric acid ester, and 5-25 wt. % oxybutynin. Another significant patent involves a transdermal therapeutic system containing pergolide. This invention also facilitates the transcutaneous administration of pergolide over several days, employing a solvent-free manufacturing method. The TTS consists of a matrix mass that includes pergolide and is structured as a layer, utilizing a (meth)acrylate copolymer with ammonio groups or a mixture of copolymers, along with 10-50% by weight propylene glycol and up to 5% by weight pergolide.

Career Highlights

Andreas Kollmeyer-Seeger is associated with Schwarz Pharma AG, where he has been instrumental in developing innovative therapeutic systems. His expertise in transdermal drug delivery systems has positioned him as a key figure in pharmaceutical advancements.

Collaborations

He has collaborated with notable colleagues such as Christoph Arth and Stephan Rimpler, contributing to the success of various projects within the company.

Conclusion

Andreas Kollmeyer-Seeger’s contributions to transdermal therapeutic systems exemplify his commitment to innovation in the pharmaceutical industry. His patents reflect a dedication to improving drug delivery methods, ultimately benefiting patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…